HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,054 | +8.2% | 969,999 | +2.2% | 0.05% | +20.5% |
| Q2 2023 | $34,244 | +8.3% | 949,387 | +14.6% | 0.04% | +4.8% |
| Q1 2023 | $31,631 | -30.5% | 828,250 | +3.5% | 0.04% | -32.3% |
| Q4 2022 | $45,525 | -99.9% | 800,091 | -16.4% | 0.06% | +12.7% |
| Q3 2022 | $37,860,000 | -11.5% | 957,511 | -1.5% | 0.06% | -1.8% |
| Q2 2022 | $42,777,000 | -0.2% | 972,197 | -9.6% | 0.06% | +21.7% |
| Q1 2022 | $42,870,000 | -15.3% | 1,074,977 | -14.6% | 0.05% | -9.8% |
| Q4 2021 | $50,642,000 | -28.8% | 1,259,450 | -28.0% | 0.05% | -32.9% |
| Q3 2021 | $71,162,000 | -3.0% | 1,749,309 | +8.3% | 0.08% | 0.0% |
| Q2 2021 | $73,352,000 | +4.8% | 1,615,323 | -3.7% | 0.08% | -1.3% |
| Q1 2021 | $69,962,000 | +2.5% | 1,678,138 | +5.1% | 0.08% | +1.3% |
| Q4 2020 | $68,224,000 | +56.2% | 1,597,382 | -3.9% | 0.08% | +43.4% |
| Q3 2020 | $43,668,000 | -2.0% | 1,661,656 | 0.0% | 0.05% | -7.0% |
| Q2 2020 | $44,549,000 | +61.0% | 1,661,656 | +8.0% | 0.06% | +35.7% |
| Q1 2020 | $27,678,000 | +77.8% | 1,538,499 | +75.2% | 0.04% | +121.1% |
| Q4 2019 | $15,567,000 | -2.5% | 878,019 | -14.7% | 0.02% | -5.0% |
| Q3 2019 | $15,967,000 | +2.4% | 1,029,443 | +13.5% | 0.02% | 0.0% |
| Q2 2019 | $15,588,000 | -1.0% | 907,353 | -7.3% | 0.02% | 0.0% |
| Q1 2019 | $15,753,000 | +2.7% | 978,449 | -6.6% | 0.02% | -9.1% |
| Q4 2018 | $15,333,000 | -17.2% | 1,048,054 | +2.9% | 0.02% | 0.0% |
| Q3 2018 | $18,511,000 | +19.7% | 1,018,770 | +11.1% | 0.02% | +15.8% |
| Q2 2018 | $15,468,000 | -10.1% | 916,884 | +4.4% | 0.02% | -9.5% |
| Q1 2018 | $17,208,000 | +0.4% | 878,396 | +3.8% | 0.02% | 0.0% |
| Q4 2017 | $17,137,000 | +17.4% | 845,875 | +0.7% | 0.02% | +10.5% |
| Q3 2017 | $14,596,000 | +51.8% | 840,284 | +12.0% | 0.02% | +46.2% |
| Q2 2017 | $9,616,000 | +9.4% | 750,041 | +10.6% | 0.01% | +8.3% |
| Q1 2017 | $8,788,000 | +81.9% | 678,108 | +38.7% | 0.01% | +71.4% |
| Q4 2016 | $4,831,000 | -5.3% | 488,940 | +15.8% | 0.01% | 0.0% |
| Q3 2016 | $5,102,000 | +54.5% | 422,340 | +10.4% | 0.01% | +40.0% |
| Q2 2016 | $3,302,000 | -8.3% | 382,670 | +0.6% | 0.01% | -16.7% |
| Q1 2016 | $3,601,000 | -44.3% | 380,290 | +2.0% | 0.01% | -40.0% |
| Q4 2015 | $6,460,000 | +35.9% | 372,785 | +5.4% | 0.01% | +25.0% |
| Q3 2015 | $4,752,000 | -49.0% | 353,845 | -14.3% | 0.01% | -42.9% |
| Q2 2015 | $9,322,000 | +136.4% | 412,835 | +49.5% | 0.01% | +133.3% |
| Q1 2015 | $3,943,000 | – | 276,130 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |